LY 517717

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H529428

CAS#: 313489-71-3

Description: LY 517717 is a coagulation factor Xa inhibitor potentially for the treatment of venous thromboembolism (VTE).


Chemical Structure

img
LY 517717
CAS# 313489-71-3

Theoretical Analysis

Hodoodo Cat#: H529428
Name: LY 517717
CAS#: 313489-71-3
Chemical Formula: C27H33N5O2
Exact Mass: 459.26
Molecular Weight: 459.594
Elemental Analysis: C, 70.56; H, 7.24; N, 15.24; O, 6.96

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: LY 517717; LY517717; LY-517717

IUPAC/Chemical Name: (R)-N-(2-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-2-oxo-1-phenylethyl)-1H-indole-6-carboxamide

InChi Key: VYNKVNDKAOGAAQ-RUZDIDTESA-N

InChi Code: InChI=1S/C27H33N5O2/c1-30-13-10-23(11-14-30)31-15-17-32(18-16-31)27(34)25(21-5-3-2-4-6-21)29-26(33)22-8-7-20-9-12-28-24(20)19-22/h2-9,12,19,23,25,28H,10-11,13-18H2,1H3,(H,29,33)/t25-/m1/s1

SMILES Code: O=C(C1=CC2=C(C=C1)C=CN2)N[C@H](C3=CC=CC=C3)C(N4CCN(C5CCN(C)CC5)CC4)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 459.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost. 2007 Apr;5(4):746-53. PubMed PMID: 17408408.

2: Perzborn E. Factor Xa inhibitors--new anticoagulants for secondary haemostasis. Hamostaseologie. 2009 Aug;29(3):260-7. PubMed PMID: 19644596.

3: Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1238-47. Review. PubMed PMID: 17379841.

4: Denas G, Pengo V. Investigational anticoagulants for hematological conditions: a new generation of therapies. Expert Opin Investig Drugs. 2013 Oct;22(10):1281-94. doi: 10.1517/13543784.2013.821463. Review. PubMed PMID: 23876036.

5: Ahrens I, Peter K, Lip GY, Bode C. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. Discov Med. 2012 Jun;13(73):445-50. Review. PubMed PMID: 22742650.

6: Bondarenko M, Curti C, Montana M, Rathelot P, Vanelle P. Efficacy and toxicity of factor Xa inhibitors. J Pharm Pharm Sci. 2013;16(1):74-88. Review. PubMed PMID: 23683607.

7: Romualdi E, Ageno W. Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. Expert Opin Investig Drugs. 2011 Apr;20(4):495-505. doi: 10.1517/13543784.2011.562190. Review. PubMed PMID: 21385107.

8: Norman P. Fragments 2007--what has fragment-based drug discovery delivered for medicinal chemistry? 7 March 2007, Cambridge, UK. IDrugs. 2007 May;10(5):313-6. PubMed PMID: 17487781.

9: Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost. 2008 Feb;34(1):39-57. doi: 10.1055/s-2008-1066023. Review. PubMed PMID: 18393142.

10: Imberti D, Dall'Asta C, Pierfranceschi MG. Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med. 2009 Dec;4(6):471-7. doi: 10.1007/s11739-009-0293-9. Review. PubMed PMID: 19696978.

11: Hampton T. New oral anticoagulants show promise. JAMA. 2006 Feb 15;295(7):743-4. PubMed PMID: 16478891.

12: Imberti D, Prisco D. Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review. Pathophysiol Haemost Thromb. 2008;36(5):217-26. doi: 10.1159/000252816. Review. PubMed PMID: 19996630.

13: Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008 Jan;29(2):155-65. Review. PubMed PMID: 18096568.

14: Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs. 2006 Aug;15(8):843-55. Review. PubMed PMID: 16859389.